THTibor Hlavaty

Tibor Hlavaty

*This is an algorithmically generated author record based on publicly available information.

Tibor Hlavaty has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Novel unorthodox strategies to reduce the case fatality rate of COVID-19 in high risk groups

    by T. Hlavaty, A. Krajcovicova

    Novel unorthodox strategies to reduce the case fatality rate of COVID-19 in high risk groups including patients using ace inhibitors


  • Guidelines of the IBD working group of the SGS on the management on the IBD – optimizing biological treatment in the IBD after loos of response.

    by Miloš Greguš, Tibor Hlavatý, Anna Krajčovičová, Laura Gombošová, Tomáš Koller, Martin Huorka, Mária Zakuciová, Igor Šturdík

  • Does Crohn's disease have an effect on female fertility?

    by Jana Kollerova, Tomas Koller, Barbora Kadleckova, Jozef Toth, Anna Krajcovicova, Tibor Hlavaty, Juraj Payer

    Introduction: Impaired fertility in women with Crohn’s disease compared to healthy women seems to be a consequence of Crohn’s disease, according to older studies. However, data are not consistent, and it is not clear why could the reduced fertility occur. Influence on ovarian reserve might be one of the answers. Patients: The study group consisted of women with Crohn’s disease. The control group consisted of age and BMI matched healthy women with no history of assisted reproduction. Methods: All patients completed a personal questionnaire, focused on fertility parameters as well as the Crohn’s disease phenotype, activity and treatment. Ovarian reserve was measured by the serum concentration of anti-mullerian hormone (AMH). In patients with Crohn’s disease, we investigated the effect of the Crohn’s disease phenotype and prior treatment on the ovarian reserve. Results: We included 50 women with Crohn’s disease and 50 controls. Comparing two groups, we did not observe any difference in rates of birth, spontaneous abortion, contraceptive use and age of menarche. Serum AMH was not different between the groups (3.026 vs. 3.19, P=0.74), 54 vs. 52% of women had an optimal ovarian reserve (AMH>2.27), and 23.7 vs. 19.23% had low ovarian reserve (AMH P=0.04) and the trend towards the more pronounced decline in L2 colic phenotype compared to L1 and L3 (slope −0.33 vs. −0.14, P=0.12). Finally, women older than 30 years had a more pronounced age-related AMH decline if Crohn’s disease lasted for more than 5 years (slope −0.31 vs. −0.2, P=0.029). Conclusion: We found that women with Crohn’s disease as compared to controls had the same ovarian reserve and equal rate of its age-related decline. More pronounced age-related decrease in ovarian reserve was observed in women with prior IBD surgery and those over 30 years of age with Crohn’s disease lasting for more than 5 years. In these cases, patients may be advised not to delay a pregnancy.

    • 21 June 2016
      • Vol. 62  (5) , 351-9

    [Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis].

    by Tomáš Koller, Zuzana Piešťanská, Tibor Hlavatý, Jozef Holomáň, Jozef Glasa, Juraj Payer

    Hepatic transit times measured by the contrast enhanced ultrasonography and liver elasticity were found to predict a clinically significant portal hypertension. However, these modalities we not yet sufficiently evaluated in predicting adverse clinical outcome in patients with clinically diagnosed cirrhosis (D´Amico stages > 1), having a clinically significant portal hypertension. The aim of our study was to assess the predictive power of the liver transit times and the liver elasticity on an adverse clinical outcome of clinically diagnosed cirrhosis compared with the MELD score. The study group included 48 consecutive outpatients with cirrhosis in the 2., 3. and 4. DAmico stages. Patients with stage 4 could have jaundice, patients with other complications of portal hypertension were excluded. Transit times were measured from the time of intravenous administration of contrast agent (Sonovue) to a signal appearance in a hepatic vein (hepatic vein arrival time, HVAT) or time difference between the contrast signal in the hepatic artery and hepatic vein (hepatic transit time, HTT) in seconds. Elasticity was measured using the transient elastography (Fibroscan). The transit times and elasticity were measured at baseline and patients were followed for up for 1 year. Adverse outcome of cirrhosis was defined as the appearance of clinically apparent ascites and/or hospitalization for liver disease and/or death within 1 year. The mean age was 61 years, with female/male ratio 23/25. At baseline, the median Child-Pugh score was 5 (IQR 5.0-6.0), MELD 9.5 (IQR 7.6 to 12.1), median HVAT was 22 s (IQR 19-25) and HTT 6 (IQR 5-9). HTT and HVAT negatively correlated with Child-Pugh (-0.351 and -0.441, p = 0.002) and MELD (-0.479 and -0.388, p = 0.006) scores. The adverse outcome at 1-year was observed in 11 cases (22.9 %), including 6 deaths and 5 hospitalizations. Median HVAT in those with/without the adverse outcome was 20 seconds (IQR 19.3-23.5) compared with 22 s (IQR 19-26, p = 0.32). Cases with adverse outcome had significantly higher MELD (12.9 vs 8.5), Child-Pugh score (7.0 vs 5.0) and the liver elasticity (52.5 vs 21.5 kPa) (p < 0.05). The AUROC of the HVAT, liver elasticity and MELD for the prediction of the adverse outcome was 0.60 (95% CI 0.414 to 0.785), 0.767 (0.56 to 0.98) and 0.813 (0.66 to 0.97). Unlike HVAT, the liver elasticity > 35.3 kPa increased the risk of the adverse outcome 10.3-times and MELD score > 11 points 8.5-times. In patients with clinically diagnosed cirrhosis having a clinically significant portal hypertension hepatic transit times do not predict the 1-year adverse clinical outcome. However, the liver elasticity > 35.3 kPa appears clinically useful with a prognostic value comparable with MELD. clinically diagnosed cirrhosis - hepatic transit times - liver elasticity - MELD - portal hypertension.

  • Trabecular bone score in patients with inflammatory bowel diseases

    by Anna Krajcovicova, Martin Kuzma, Aristodimos Grigorios Kaniaris, Zdenko Killinger, Tibor Hlavaty, Juraj Payer

    Introduction: Osteoporosis is known chronic complication of inflammatory bowel diseases (IBD). It is known that areal bone mineral density (aBMD) does not sufficiently reflect bone strength and quality. The trabecular bone score (TBS) provides an indirect measurement of bone microarchitecture, independent of aBMD. Aims and methods: The aim was to assess TBS in IBD patients with regard to disease behavior using in comparison with lumbar spine (LS) BMD. The cohort consisted of 84 IBD patients, 53 with Crohn’s disease (CD) and 31 with ulcerative colitis (UC). Clinical characteristics i.e. age, gender, anthropometry, clinical behaviour, medication were recorded. The BMD was determined by dual-energy X-ray absorptiometry (DXA, Hologic Discovery) at the lumbar spine. TBS was determined by TBS Insight software (Medimaps, France). Results: Cohort mean age was 42±14.2 years with the average disease duration of 11±7 years. 12/84 (14%) of the cohort were postmenopausal women. 39.6% (21/53) of CD patients had prior resection of the ileum. At the time of assessment 8/84 (9.5%) of the IBD patients (3CD vs 5 UC patients) were on glucocorticoid therapy with >5 mg equivalent to prednisolone daily. The percentage of patients with substitution of vitamin D (800IU) and calcium (0.5–1 g) was similar between CD and UC (24.5% vs 29%), none of the patients were on antiporothic treatment. The average LS BMD was 0.964±0.113 g/cm2 and TBS 1.36±0.14. Significantly lower TBS although not LS BMD was found in patients with fistulising CD as compared to those with luminal disease (P=0.0039). We did not observe any difference in TBS or BMD in UC patients according to the disease behaviour. Conclusion: We observed that spine TBS can identify quality of bone mineral density in patients with Crohn’s disease better than BMD itself. CD patients with severe disease are at higher risk of low bone mineral density.

  • Is testosterone deficiency a real problem of male IBD patients?

    by Jana Kollerova, Tibor Hlavaty, Anna Krajcovicova, Zuzana Leskova, Tomas Koller, Juraj Payer

    There have been many discussions about testosterone role in inflammation and autoimmunity. Inflammatory bowel disease (IBD) is a chronic autoimmune disease in younger age groups. The aim ouf our study was to evaluate testosterone concentration and it’s influence on disease acitivity and the quality of life. In our cross-sectional study we measured total testosterone levels in males with IBD (Crohn’s Disease, Ulcerative colitis). Age, BMI, main characteristics of IBD were also recorded as well as the disease activity (Harvey-Bradshaw Index for CD and Mayo score for UC) and the quality of life (SIBDQ). We included 113 patient with IBD (CD 66, UC 47) with median age of 34 (CD) and 41 (UC) years. Disease was active in 10.6% of CD and 14.9% UC patients. Median duration of disease was 10.05 and 8.9 years respectively. The median testosterone concentration was 11 nmol/l for both groups. The level was less than 10 nmol/l in 34% and lower than 6 nmol/l in 4% of patients. We found a slight negative correlation of testosterone with disease activity in UC (R=0.28, P=0.06) and slight negative correlation to CRP in all IBD patients (R=0.2, P=0.03). There was also negative correlation between IBD duration and testosterone (R=0.18, P=0.058). The quality of life did not correlate with TST levels. Testosterone deficiency in quite common among male IBD patients. It seems to be connected to the disease activity, inflammation and the duration of disease. Very low concentration of testosterone was rarely found. The quality of life seemed not to be affected while most cases were in the clinical remission.


  • Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases – a one-year, single-centre retrospective study

    by Tibor Hlavatý, Anna Krajčovičová, Igor Šturdík, Juraj Letkovský, Tomáš Koller, Jozef Tóth, Martin Huorka


    • 1 February 2016
      • Vol. 62  (2) , 147-51

    [Fecal microbiota transplantation].

    by Igor Šturdík, Tibor Hlavatý, Juraj Payer

    Fecal microbiota transplantation (FMT) is a therapeutic method, in which the fecal microflora from healthy donors is transmitted to the patient to restore the healthy microbial composition of the gut. In the recent years, there is a growing interest in the therapeutic potential of FMT in various diseases. The standard FMT protocols do not exist. Procedures of FMT vary in several aspects such as donor selection, preparation of fecal material, preparation of the recipient and administration way. FMT appears to be the most successful in the treatment of recurrent Clostridium difficile infection (CDI), randomized controlled studies reported 90 % success rate. There is a limited evidence for FMT as a treatment of ulcerative colitis. FMT has been also studied as treatment of diseases with impaired gut microbiota, such as cardiovascular, autoimmune and metabolic diseases. Many unanswered questions with regard to FMT remain and further research is needed.